logo

Redhill Biopharma Ltd. (RDHL)



Trade RDHL now with
  Date
  Headline
12/31/2020 9:33:53 AM RedHill Biopharma Reports Preliminary Top-line Data From U.S. Phase 2 Study With Orally-administered Opaganib
12/22/2020 7:11:12 AM RedHill's Phase 2/3 COVID-19 Study Of Opaganib Passes Second DSMB With Unanimous Recommendation To Continue
12/15/2020 9:32:04 AM RedHill's Phase 2/3 COVID-19 Candidate Opaganib Reduces ARDS-Related Blood Clotting In Preclinical Model
12/7/2020 7:22:55 AM RedHill Biopharma Extends Talicia Unrestricted National And Regional Commercial Coverage To Over 40 Mln Addl Americans
11/20/2020 8:05:17 AM RedHill Initiates Phase 3 Study Of RHB-204 For First-Line Treatment Of NTM Disease
11/17/2020 7:20:26 AM RedHill Biopharma Says FDA Cleared IND Application For Phase 2/3 Study Evaluating Orally Administered RHB-107
11/16/2020 10:15:51 AM RedHill Biopharma Completes Enrollment For COVID-19 U.S. Phase 2 Study With Opaganib
10/14/2020 11:06:37 AM RedHill Announces FDA Orphan Drug Designation For RHB-204 For Treatment Of NTM Infections
10/13/2020 10:44:40 AM RedHill Announces Partnerships To Expand Manufacturing For COVID-19 Therapeutic Candidate Opaganib
10/8/2020 10:42:38 AM RedHill Obtains Israel Rights To Movantik From AstraZeneca, Giving RedHill Global Rights, Excluding Europe And Canada
10/7/2020 10:14:38 AM RedHill Biopharma Says Its Opaganib COVID-19 Study Passes Second Independent Committee Review
9/22/2020 10:26:35 AM Brazil Oks RedHill Biopharma’s Phase 2/3 COVID-19 Study With Opaganib